Pfizer's oncology promises are several years from being actualized. Read why investors shouldn't assume that a sustained ...

Pfizer said Tuesday it does not expect the Trump administration to make major changes to vaccine policy next year even with ...

Pfizer is fending off investors’ fears about threats to its vaccine business under the Trump administration.

Pharmaceuticals giant Pfizer closed Tuesday's session nearly 5% in the green, after it issued an upbeat full-year outlook for ...

( MENAFN - Baystreet) Shares in health Insurers fell again. On Tuesday, Pfizer's (PFE) CEO, Albert Bourla, revealed that ...

Charting, Price Performance, News & Related Contracts.

In addition to Bourla, other famous Jews with roots in Thessaloniki include actor Hank Azaria, Israeli businessman and ...

Activist investor Starboard Value has launched a broadside against Pfizer's leadership under chief executive Albert Bourla, claiming at least $20 billion in value – and possibly as much as $60 ...

Pfizer said it had achieved $4 billion in net cost savings through 2024 and that it expects full-year 2025 revenue to range ...

Pfizer has promoted Albert Bourla, seen as a likely successor to incumbent CEO Ian Read, to the newly-created role of chief operating officer. The move could help Read focus on long-term strategy ...

Pfizer’s financial challenges are offset by growth potential in oncology and strong dividends. Learn why PFE stock is a "Buy" ...